Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000355347

Medchemexpress LLC 3-Isoquinolinamine, N-[2-[(3S,4R)-3-fluoro-4-methoxy-1-piperidinyl]-4-pyrimidinyl]-5-(1-met | 2660250-10-0 | 99.4% | C28H37FN6O3S | 50 MG
SDP

Catalog No. 5000355347
Encompass_Preferred

BLU-945 is a potent, highly selective, reversible, and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. This product is used for the research of lung cancer, including non-small cell lung cancer (NSCLC).

  • Potent and highly selective EGFR tyrosine kinase inhibitor
  • Reversible and orally active
  • Inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation
  • Used for research of lung cancer, including non-small cell lung cancer
  • Shows inhibitory activity against EGFRm/T790M double and EGFRm/T790M/C797S triple mutants
  • Demonstrates robust EGFR pathway inhibition and anti-tumor activity in triple-mutant Osimertinib-resistant models

Catalog No. 50-003-55347 Supplier Medchemexpress LLC Supplier No. HY14468050MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

BLU-945 is a potent, highly selective, reversible, and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. This product is used for the research of lung cancer, including non-small cell lung cancer (NSCLC).

  • Potent and highly selective EGFR tyrosine kinase inhibitor
  • Reversible and orally active
  • Inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation
  • Used for research of lung cancer, including non-small cell lung cancer
  • Shows inhibitory activity against EGFRm/T790M double and EGFRm/T790M/C797S triple mutants
  • Demonstrates robust EGFR pathway inhibition and anti-tumor activity in triple-mutant Osimertinib-resistant models

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.